DEVON, Pa., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced the acceptance and presentation details of a Late Breaking poster at the 2017 Annual Meeting of the American Epilepsy Society (AES) in Washington, DC, taking place December 1 through December 5, 2017.
Sunday, December 3, 2017
Poster title: “Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults”
Poster session: 2
Poster number: 428
Author presentation time: 12:00PM – 2:00PM EST
Display time: 10:00AM – 4:00PM EST
Location: Hall B, Lower Level
Abstract ID: 2.428
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to improving the lives of people with severe health conditions where there is a high unmet medical need by developing and commercializing pharmaceutically-produced transdermal cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Through the discovery and development of these life-changing medicines, Zynerba seeks to improve the lives of patients battling severe, chronic health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Learn more at www.zynerba.com and follow the Company on Twitter at @ZynerbaPharma.
Will Roberts, VP Investor Relations and Corporate Communications
Tonic Life Communications
Zynerba Pharmaceuticals, Inc.